A Phase II Trial of the Efficacy and Safety of Tocilizumab for Treatment of Inflammation in the Renal Allograft
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2018
At a glance
- Drugs Tocilizumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 06 Jun 2018 Results (n=22) presented at the 2018 American Transplant Congress.
- 13 Jan 2015 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018 as reported by ClinicalTrials.gov.
- 13 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.